Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 29, 2024, to June 27, 2025 [1]. - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application for oxylanthanum carbonate [1]. - As a result of these alleged misstatements, the defendants' public statements were deemed materially false and misleading throughout the relevant time [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of UNCY during the class period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for October 14, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 14, 2025 [4]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [6]. - Specific deficiencies in cGMP compliance were identified at a third-party manufacturing vendor, which were not disclosed prior to the FDA's findings [7]. Group 2: Stock Price Impact - Following the announcement of deficiencies on June 10, 2025, Unicycive's stock price fell by $3.68 per share, a decrease of 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Legal Process and Participation - The lead plaintiff in the class action is the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [9]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - Investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, are encouraged to contact the firm to discuss their legal rights [1][4]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for oxylanthanum carbonate [7] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [7] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [7] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [7] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [7] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [7] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4][8] - The law firm represents individual and institutional investors in complex litigation across the United States [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, encouraging affected investors to discuss their legal options [1][3]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its OLC NDA [3]. - Specific claims include overstated readiness to meet FDA compliance and misrepresentation of the NDA's regulatory prospects, leading to materially false public statements [3]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, which disclosed deficiencies in cGMP compliance at a third-party vendor, Unicycive's stock price fell by $3.68, or 40.89%, closing at $5.32 per share [4]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same cGMP deficiencies, the stock price dropped by $2.03, or 29.85%, closing at $4.77 per share [5]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive is October 14, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member, with no impact on their ability to share in any recovery [6].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly making false and misleading statements regarding its FDA approval prospects for a treatment related to hyperphosphatemia in chronic kidney disease patients on dialysis [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 29, 2024, to June 27, 2025, with a deadline for lead plaintiff appointments set for October 14, 2025 [2]. - The complaint alleges that Unicycive was overly optimistic about the chances of FDA approval for its treatment, leading to materially misleading public statements throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. alleging securities fraud that affected investors between March 29, 2024, and June 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - It is alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [2]. - The defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that Unicycive made false or misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in annual securities class action settlements since 2013 [4].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - A subsequent Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, caused the stock to drop nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4][5] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4]